Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211223 | 0.88 | TLR7 (0.51) | TLR7 | |
| SCHEMBL213130 | 0.87 | TLR7 (0.69) | TLR7 | |
| SCHEMBL5136457 | 0.81 | TLR7 (0.46) | TLR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL212611 | 0.79 | TLR7 (0.51) | TLR7MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL212714 | 0.79 | TLR7 (0.51) | TLR7 | |
| SCHEMBL24733513 | 0.75 | ALDH1A1 (0.51) | TLR7MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL213070 | 0.75 | MEN1 (0.43) | TLR7MAPTKMT2A | |
| SCHEMBL9601995 | 0.75 | TLR7 (0.73) | TLR7KMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL213639 | 0.74 | TSHR (0.47) | TLR7MAPTKMT2AALDH1A1 | |
| SCHEMBL211357 | 0.74 | TLR7 (0.38) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | TLR7 58/4885MAPT 4616/4885KMT2A 2108/4885 |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | TLR7 58/4885MAPT 4616/4885KMT2A 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.